Evolution of FMT – From Early Clinical to Standardized Treatments
A Virtual Meeting
15:00 - 18:00 CEST // 9:00am - 12:00pm EDT

Current Efforts in African Swine Fever Vaccines
A Virtual Seminar and Discussion

Thursday, May 6, 2021
9:00 AM - 12:30 PM EDT

Link to the video recording

Speakers from the U.S., Europe, Africa, and China will discuss recent developments in
African Swine Fever Vaccines including
licensing, regulation, and commercialization.


Click here to see the website

Human Infection Studies
Considerations on manufacturing of challenge agents-
viruses (SARS-CoV-2/COVID-19) and parasites as examples

A Joint Wellcome Trust/HIC-Vac, hVIVO and IABS webinar
March 31, 2021
2pm (UK TIME) / 3pm (CET) / 9am (US EST) – 5pm (UK time) / 6pm (CET) / 12 :00noon (US EST)

Platform Technology: Is it possible to reduce vaccine development time?

An IABS webinar: Thursday, February 18, 2021 from 14 :00 – 16 :30 CET

Testimonials from J&J, Curevac and BioNtech

Round table discussion with Industry, EMA, FDA, Health Canada, PEI, WHO…

Meeting Report Now Available

Platform Technology: what are the first experiences from different players who were allowed by the authorities to use data from other programs in a platform technology approach in order to shorten the development time.

ZAPI Stakeholders Final Conference
February 4-5, 2021
A Virtual Meeting


INFORMATION ABOUT THE MEETING HERE

REQUEST THE SPEAKER SLIDES


In March 2015, IMI  (Innovative Medicine Initiative - https://www.imi.europa.eu) launched ZAPI (Zoonotic Anticipation and Preparedness Initiative) to set up methodologies and platform technologies that would be ready to put into production for vaccines and neutralizing monoclonal antibodies to efficiently counter emerging or remerging zoonotic viruses.

“The objective is to demonstrate that we can deliver on these platforms, using three different prototype models of diseases that occurred in the recent past and which are zoonotic in nature.” The viruses that [have been] used as models are Middle East respiratory syndrome coronavirus (MERS-CoV); Schmallenberg virus; and Rift Valley Fever virus’. IMI ZAPI Interview

Six years later, the ZAPI project has made great strides in vaccine and antibody design, and new approaches for achieving the “surge manufacturing capacity” objective.

The Final Stakeholders Global Meeting will present an overview of the main findings and key learnings from the ZAPI project partnership’s experience for improving our One Health preparedness status for facing effectively future pandemics.

The ZAPI project benefits from the assistance and financial support of
IMI and the European Commission, and in-kind contributions from EFPIA partners.

6th IABS Statistics Workshop:
Approaches for Improving Statistical Partnership in CMC Development,
Manufacturing, and Regulation of Biologicals

U.S. Pharrmacopeia
Rockville, Maryland

Due to restrictions associated with the SARS-COVID-2 pandemic,
the 6th IABS Statistics Workshop was held virtually.

Visit the meeting website

Approaches for Improving Statistical Partnership in CMC Development, Manufacturing, and Regulation of Biologicals was the 6th meeting in the series of IABS workshops focusing on Statistics and the role they play in the development of biotherapeutics and vaccines.

Read the Summary of the Meeting

An Update on SARS-CoV-2
Friday, October 16,
2020
14:00-16:00 CEST

The first IABS webinar (May 27th) provided insight into what was known at that point in time about SARS-CoV-2:
the epidemiology worldwide; the disease from an immunology viewpoint and the development of vaccines against the virus.


This 3rd International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of
international stakeholders, including academia, regulators, funders and industry, with a considerable delegation
from low- and middle-income countries, to provide an update on
the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2,
six months after the previous webinar.

 Although SARS-CoV-2 shows limited evolution, which is beneficial for vaccine development,
recombination of SARS-CoV-2 with another CoV has led to enhanced human-to-human transmissibility of the virus.


Read the Meeting Report

Read the Summary

 

IABS Webinar
SARS-CoV-2
Controlled Human Infection Models (CHIM):
Ethics, Challenge Agent
Production, and Regulatory Issues
June 23rd, 2020 : 14:00-18:00 CEST

 IABS has been asked to organize several webinars in order to share scientific information on SARS-CoV-2.

The first IABS webinar (Wednesday May 27th,14:00-16:00 CEST)  provided an insight to what was known to date about
the epidemiology worldwide, the disease from an immunology viewpoint and progress regarding the development of vaccines against the virus.

The second IABS SARS CoV-2 webinar was devoted to the use of controlled human infection models (CHIM) to accelerate development and market authorization assessment of vaccines against the virus. The webinar consisted of four brief presentations to set the stage, followed by three panel discussions on ethics, challenge agent production
and quality control issues (CMC) and regulatory issues, and provided ample time for discussion between panelists and participants.
The webinar was organized under the Chatham House Rule (https://www.chathamhouse.org): participants are free to use the information received, but neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed.

The next IABS SARS CoV-2 webinar: Friday, October 16, 2020.

Read the Meeting Report

IABS Webinar
Update on SARS-CoV-2
May 27th,  2020 : 14:00 CEST

IABS has been asked to organize several webinars in order to share scientific information on SARS-CoV-2.

As science is evolving day after day, it is important for many people to have an overview of the actual knowledge at a specific moment in time.

The first IABS webinar that took place Wednesday May 27th from 14:00-16:00 CEST gave you an insight to what is known about SARS-CoV-2, the epidemiology worldwide, the disease from an immunology viewpoint and where we are today with the development of vaccines against the virus.

This webinar is the first in a series of webinars to inform our network on what is known about the virus, the disease, and how to cope with it.

 Read the Meeting Report

The recording of the webinar is available below:

 New paths for sustainable solutions to tackle global and emerging infectious threats

Read the Meeting Report

Visit the meeting website

 IABS celebrated its 65th Anniversary on February 26-28, 2020, in Lyon, France.

3rd Human Challenge Trials in Vaccine Development

Read the Meeting Report

 Visit the meeting website

5th IABS Cell Therapy Conference
Towards international convergence of basic technical requirements
and evaluation of human cell therapy products

Muromachi Mitsui Hall & Conference
Tokyo, Japan
Organized by: International Alliance for Biological Standardization (IABS)

With the support from: Osaka University Graduate School of Medicine

Visit the meeting website

Animal Testing for Vaccines
Implementing Replacement, Reduction and Refinement:

Challenges and Priorities

Information about the meeting here

View the Speaker Slides

Read the Meeting Report



2nd Setting Specifications for Biological Products: A Pathway to Harmonization

Information about the meeting here

2nd Conference on Next Generation Sequencing
for Adventitious Virus Detection in
Human and Veterinary Biologics

An IABS-EU Meeting

Read the Meeting Report

 

Quality Requirements for Challenge Agents
An IABS-EU Meeting

Read the Meeting Report 

Towards Rabies Elimination in Asia-Pacific – From Theory to Practice

 

Read the Meeting Report

Meeting objectives
The meeting aims at snowballing efforts and achieving substantial progress in rabies control in the Asia-Pacific region of the world in the near future. As the key focus is placed on canine rabies the meeting will be an important contribution to the initiative of the United Against Rabies collaboration of the World Health Organization (WHO), World Organisation for Animal Health (OIE), Food and Agriculture Organization of the United Nations (FAO), and Global Alliance for Rabies Control (GARC) of ending human dog-mediated rabies by 2030. Recognized international and local experts will give insights into state-of-the art intersectoral One Health approaches, standards, available tools and guidelines developed by international organizations and institutions and best-practice examples from the region on how to prevent human rabies by eliminating rabies at its animal source. As such the meeting provides a platform for health and veterinary services, managers of national and local rabies eliminations programs, researchers and other people interested in advancing knowledge of rabies surveillance, prevention and control, to meet each other, to share their experience and also to discuss challenges to overcome. The meeting is considered to be a starting point for a continuous professional exchange on the way to a rabies free Asia-Pacific.

Scientific Committee :

Dr Charung Muangchana Director, National Veterinary Institute, Thailand
Dr Karoon Chanachai, Department of Livestock Development (DLD), Thailand
Dr Thomas Müller, Chair Friedrich-Loeffler-Institut, Germany
Dr Conrad Freuling, Friedrich-Loeffler-Institut, Germany
Dr Bernadette Abela-Ridder, World Healandh Organization
Dr Ivana Knezevic, World Health Organization
Dr Gregorio Torres, World Organization for Animal Health (OIE)
Dr Katinka de Balogh, Food and Agricultural Organization of the UN (FAO)
Dr Carmen Jungbäck, International Alliance for Biological Standardization (IABS)
Dr Gowri Yale, Mission Rabies
Prof. Louis Nel,Global Alliance for Rabies Control
Dr Ryan Wallace, Centres for Disease Control and Prevention, USA

 

Workshop on
Diagnostics in the Veterinary Field:
The Role in Health Surveillance and Disease Identification

A workshop focusing on advantages / benefits and disadvantages
and gaps of the current methods and methodologies

Read the Meeting Report

 

 

Workshop: Implementing Non-animal Approaches to Human and Veterinary Vaccine Testing:
Achieving Scientific and Regulatory Success for Rabies and Beyond
October 16-17, 2018
National Institutes of Health, Bethesda, Maryland

 Read the Meeting Report

 

The workshop agenda as well as speaker and poster abstracts are included in the e-book. The e-book and speaker slides are posted on the web (e-book* and slides**).

International Alliance for Biological Standardization


Twitter Feed

@NCICancerBio Thanks to Dr Phil Daschner ! more info : https://t.co/VNvQGQ2Gx1
#IABSnews We are proud to welcome Norman W. Baylor in the position of Editor-in-Chief of IABS' Journal BIOLOGICALS… https://t.co/agXaGj099U
Follow IABS_global on Twitter

Contact Info

IABS, Rue Mina-Audemars, 3
CH-1204 Geneva

Switzerland
+ 41 22 301 10 36
This email address is being protected from spambots. You need JavaScript enabled to view it.